Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Self-reporting limits Pfizer's corrupt practices penalties as US widens industry net

This article was originally published in Scrip

Executive Summary

Pfizer has paid $60.2 million in fines and disgorgement of profits plus interest over violations of the US Foreign Corrupt Practices Act (FCPA). But the pharma giant avoided criminal prosecution and long-term government oversight of itself and its US executives by reporting bribes in several European and Asian countries to the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) before an employee or third-party could allege illegal activity.

You may also be interested in...



Abbott’s Medical Camps In India: Genuine Effort or Proxy Sales Plan?

US multinational Abbott is under fire in India for allegedly using medical “camps” and a questionable “survey” approach to bolster prescriptions for its diabetic neuropathy drug, Surbex Star. Abbott has strongly denied any wrong-doing but some experts suggest it’s probably tough to delink the rub-off such activities could have on brand building.

Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020

Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018396

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel